Indian Journal of Ophthalmology

REVIEW ARTICLE
Year
: 2018  |  Volume : 66  |  Issue : 12  |  Page : 1727--1735

Current management strategy of polypoidal choroidal vasculopathy


Christine P S Ho1, Timothy Y Y Lai2 
1 Faculty of Medicine, The University of Hong Kong; 2010 Retina and Macula Centre, Kowloon, Hong Kong SAR
2 Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, The Chinese University of Hong Kong; 2010 Retina and Macula Centre, Kowloon, Hong Kong SAR

Correspondence Address:
Dr. Timothy Y Y Lai
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon
Hong Kong SAR

Polypoidal choroidal vasculopathy (PCV) is a retinal disorder commonly found in Asians presenting as neovascular age-related macular degeneration and is characterized by serous macular detachment, serous or hemorrhagic pigment epithelial detachment, subretinal hemorrhage, and occasionally visible orange-red subretinal nodular lesions. PCV is diagnosed using indocyanine green angiography (ICGA), and the lesions appear as polypoidal aneurysmal vascular lesions with or without abnormal branching vascular network. Although ICGA remains the gold standard for the diagnosis of PCV, various imaging modalities have also facilitated the diagnosis and monitoring of PCV. Recent advances in imaging technology including the use of high resolution spectral domain optical coherence tomography (OCT) and OCT angiography have provided new insights on the pathogenesis of PCV, suggesting a link between PCV and pachychoroid spectrum of macular disorders. With the evolving understanding on the pathogenesis and clinical characteristics of PCV, different therapeutic options have been proposed. These include intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy, combination therapy with anti-VEGF and verteporfin photodynamic therapy, and thermal laser photocoagulation. In recent years, major multi-center randomized clinical trials such as EVEREST, EVEREST II, and PLANET studies have been conducted to compare the efficacy and safety of various treatment options for PCV. This review aims to summarize the results of recent literature, clinical trials and studies to provide an update on the management options of PCV. An overall management strategy for PCV will also be proposed.


How to cite this article:
Ho CP, Lai TY. Current management strategy of polypoidal choroidal vasculopathy.Indian J Ophthalmol 2018;66:1727-1735


How to cite this URL:
Ho CP, Lai TY. Current management strategy of polypoidal choroidal vasculopathy. Indian J Ophthalmol [serial online] 2018 [cited 2019 Aug 24 ];66:1727-1735
Available from: http://www.ijo.in/article.asp?issn=0301-4738;year=2018;volume=66;issue=12;spage=1727;epage=1735;aulast=Ho;type=0